Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,543 JPY | -0.66% | +0.71% | -18.37% |
31/03 | A second Kobayashi Pharma Japan factory inspected over deaths | RE |
30/03 | Kobayashi factory searched over deaths possibly linked to supplements | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.37% | 2.61B | C+ | ||
+8.76% | 129B | B- | ||
+14.18% | 74.67B | A+ | ||
-16.59% | 62.59B | A- | ||
+0.82% | 52.86B | B+ | ||
-12.40% | 36.11B | - | ||
+3.54% | 33.57B | B- | ||
+7.92% | 17.29B | A- | ||
+6.30% | 14.75B | B | ||
-8.65% | 10.82B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4967 Stock
- Ratings Kobayashi Pharmaceutical Co., Ltd.